| 10.4775 -0.613 (-5.52%) | 01-29 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 14.7 | 1-year : | 17.17 |
| Resists | First : | 12.59 | Second : | 14.7 |
| Pivot price | 9.47  |
|||
| Supports | First : | 8.56 | Second : | 6.08 |
| MAs | MA(5) : | 11.08 |
MA(20) : | 8.92 |
| MA(100) : | 10.12 |
MA(250) : | 28.91 |
|
| MACD | MACD : | 0.7 |
Signal : | 0.4 |
| %K %D | K(14,3) : | 73 |
D(3) : | 81.9 |
| RSI | RSI(14): 59.5 |
|||
| 52-week | High : | 399 | Low : | 6.08 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ RNAZ ] has closed below upper band by 30.9%. Bollinger Bands are 50.4% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 3 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 10.81 - 10.88 | 10.88 - 10.93 |
| Low: | 9.75 - 9.84 | 9.84 - 9.9 |
| Close: | 10.37 - 10.49 | 10.49 - 10.58 |
TransCode Therapeutics, Inc., a biopharmaceutical company, engages in the development and commercialization of drugs and diagnostics for treating and identifying metastatic disease. Its lead therapeutic candidate, TTX-MC138, is a preclinical stage product for the treatment of metastatic cancer. The company's products in preclinical programs include TTX-siPDL1, an siRNA-based modulator of programmed death-ligand 1; TTX-siLIN28B, an siRNA-based inhibitor of RNA-binding protein LIN28B. Its cancer agnostic programs comprise TTX-RIGA, an RNAbased agonist of the RIG-I-driven immune response in the tumor microenvironment; TTX-CRISPR, a CRISPR/Cas9based therapy platform for the repair or elimination of cancer-causing genes inside tumor cells; and TTX-mRNA, an mRNA-based platform for the development of cancer vaccines meant to activate cytotoxic immune responses against tumor cells. The company was incorporated in 2016 and is based in Boston, Massachusetts.
Tue, 06 Jan 2026
TransCode Therapeutics Announces Publication of Preclinical Data Supporting Therapeutic Potential of TTX-MC138 in Glioblastoma - PR Newswire
Sat, 27 Dec 2025
Precision Trading with Transcode Therapeutics Inc. (RNAZ) Risk Zones - Stock Traders Daily
Mon, 22 Dec 2025
TransCode Therapeutics Appoints Jack E. Stover To Board - citybiz
Wed, 08 Oct 2025
TransCode acquires Polynoma, receives $25 million investment By Investing.com - Investing.com
Wed, 08 Oct 2025
TransCode Makes Bold Bet On Melanoma Vaccine With Polynoma Buyout - Benzinga
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 1 (M) |
| Held by Insiders | 832420 (%) |
| Held by Institutions | 9.2 (%) |
| Shares Short | 38 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -1.7e+007 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -232.6 % |
| Return on Equity (ttm) | -1 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 495.46 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | -236.6 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -15 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | 0.02 |
| Price to Cash Flow | 9.43 |
| Dividend | 0 |
| Forward Dividend | 59480 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|